You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluorometholone
Accession NumberDB00324  (APRD00980)
TypeSmall Molecule
GroupsApproved
DescriptionA glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)
Structure
Thumb
Synonyms
(1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one
9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
Fluor-OP
Fluorometholon
Fluorométholone
Fluorometholone
Fluorometholonum
Fluorometolona
NSC 33001
Oxylone
External Identifiers
  • U 17323
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FlarexSuspension / drops1 mg/mLOphthalmicAlcon Laboratories, Inc.1992-02-06Not applicableUs
Flarex Oph Susp 0.1%Suspension0.1 %OphthalmicAlcon Canada Inc1987-12-31Not applicableCanada
FluorometholoneSolution / drops1 mg/mLOphthalmicPacific Pharma, Inc.1997-10-31Not applicableUs
FMLOintment1 mg/gOphthalmicAllergan, Inc.1985-12-09Not applicableUs
FMLSuspension / drops1 mg/mLOphthalmicAllergan, Inc.1972-02-01Not applicableUs
FML 0.1%Solution / drops0.1 %OphthalmicAllergan Inc1972-12-31Not applicableCanada
FML ForteSuspension / drops2.5 mg/mLOphthalmicAllergan, Inc.1986-05-01Not applicableUs
FML Forte Sus 0.25%Suspension0.25 %OphthalmicAllergan Inc1987-12-312016-04-06Canada
PMS-fluorometholoneSuspension0.1 %OphthalmicPharmascience Inc2001-07-162016-10-28Canada
Sandoz FluorometholoneSuspension0.1 %OphthalmicSandoz Canada Incorporated2012-07-24Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EfflumidexAllergan
FluatonAllergan
FlumetholonFerron
Fluor-opNovartis Ophthalmics
FlurolonAllergan
FML LiquifilmAllergan
FoxoneWinston
FucinMey See
FulusonDae Wo
FumelonHan Lim
HumetoronKuk Je
Brand mixtures
NameLabellerIngredients
FML-neo Oph SusAllergan Inc
Salts
Name/CASStructureProperties
Fluorometholone Acetate
ThumbNot applicableDBSALT001065
Categories
UNIISV0CSG527L
CAS number426-13-1
WeightAverage: 376.4617
Monoisotopic: 376.204987621
Chemical FormulaC22H29FO4
InChI KeyFAOZLTXFLGPHNG-KNAQIMQKSA-N
InChI
InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
IUPAC Name
(1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])C[[email protected]](C)C2=CC(=O)C=C[C@]12C
Pharmacology
IndicationFor the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
Structured Indications
PharmacodynamicsCorticosteroids such as fluorometholone inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.
Mechanism of actionThere is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Their primary target is the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects may include acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. LD50 = 234 mg/kg (rats)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluorometholone.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Fluorometholone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluorometholone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluorometholone.Approved
AldesleukinFluorometholone may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Fluorometholone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Fluorometholone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Fluorometholone can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluorometholone.Approved
AmiodaroneThe metabolism of Fluorometholone can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BFluorometholone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluorometholone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluorometholone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fluorometholone.Approved, Investigational
AprepitantThe serum concentration of Fluorometholone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Fluorometholone.Approved, Investigational
AtazanavirThe metabolism of Fluorometholone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Fluorometholone can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fluorometholone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluorometholone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluorometholone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluorometholone.Approved, Investigational
BazedoxifeneThe serum concentration of Fluorometholone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideFluorometholone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluorometholone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluorometholone.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Fluorometholone.Investigational
BexaroteneThe serum concentration of Fluorometholone can be decreased when it is combined with Bexarotene.Approved, Investigational
Bismuth SubcitrateThe bioavailability of Fluorometholone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe metabolism of Fluorometholone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Fluorometholone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fluorometholone can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluorometholone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluorometholone.Investigational
BumetanideFluorometholone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluorometholone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Fluorometholone can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe metabolism of Fluorometholone can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluorometholone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluorometholone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Fluorometholone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluorometholone.Approved, Investigational
CeritinibThe serum concentration of Fluorometholone can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluorometholone.Approved, Vet Approved
ChlorothiazideFluorometholone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Fluorometholone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneFluorometholone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe metabolism of Fluorometholone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Fluorometholone can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluorometholone.Approved
ClotrimazoleThe metabolism of Fluorometholone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Fluorometholone can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Fluorometholone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Fluorometholone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluorometholone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Fluorometholone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluorometholone.Investigational
CyclosporineThe metabolism of Fluorometholone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Fluorometholone.Investigational
DabrafenibThe serum concentration of Fluorometholone can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Fluorometholone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Fluorometholone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Fluorometholone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Fluorometholone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Fluorometholone.Investigational
DexamethasoneThe serum concentration of Fluorometholone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluorometholone.Approved, Vet Approved
DienestrolThe serum concentration of Fluorometholone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Fluorometholone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluorometholone.Approved
DihydroergotamineThe metabolism of Fluorometholone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneFluorometholone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Fluorometholone can be decreased when combined with Diltiazem.Approved
DonepezilThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Donepezil.Approved
DoxycyclineThe metabolism of Fluorometholone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Fluorometholone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluorometholone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluorometholone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Fluorometholone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Fluorometholone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Fluorometholone can be decreased when it is combined with Efavirenz.Approved, Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Fluorometholone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluorometholone.Approved
ErythromycinThe metabolism of Fluorometholone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Fluorometholone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Fluorometholone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Fluorometholone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Fluorometholone can be increased when it is combined with Estrone.Approved
Etacrynic acidFluorometholone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fluorometholone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Fluorometholone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluorometholone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluorometholone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluorometholone.Approved, Investigational
EtravirineThe serum concentration of Fluorometholone can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fluorometholone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Fluorometholone.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluorometholone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluorometholone.Approved
FenthionThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fluorometholone.Approved, Withdrawn
FluconazoleThe metabolism of Fluorometholone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fluorometholone.Vet Approved
FluoxymesteroneFluorometholone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluorometholone.Approved, Investigational
FluvoxamineThe metabolism of Fluorometholone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fluorometholone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fluorometholone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Fluorometholone can be increased when combined with Fosphenytoin.Approved
FurosemideFluorometholone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Fluorometholone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Fluorometholone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Fluorometholone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Fluorometholone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluorometholone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Fluorometholone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluorometholone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Fluorometholone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluorometholone.Approved, Investigational
HydrochlorothiazideFluorometholone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFluorometholone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluorometholone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fluorometholone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fluorometholone.Approved
IdelalisibThe serum concentration of Fluorometholone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Fluorometholone can be decreased when combined with Imatinib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Fluorometholone.Approved
IndapamideFluorometholone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Fluorometholone can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluorometholone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluorometholone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Fluorometholone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Fluorometholone is combined with INGN 225.Investigational
IsavuconazoniumThe metabolism of Fluorometholone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluorometholone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluorometholone.Withdrawn
IsradipineThe metabolism of Fluorometholone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Fluorometholone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fluorometholone can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluorometholone.Experimental
KetoconazoleThe metabolism of Fluorometholone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluorometholone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluorometholone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fluorometholone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluorometholone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Lomefloxacin.Approved
LopinavirThe metabolism of Fluorometholone can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluorometholone.Approved
LovastatinThe metabolism of Fluorometholone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluorometholone.Approved
LuliconazoleThe serum concentration of Fluorometholone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Fluorometholone can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluorometholone.Approved, Investigational
MagaldrateThe bioavailability of Fluorometholone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Fluorometholone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Fluorometholone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Fluorometholone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluorometholone.Approved
Magnesium TrisilicateThe bioavailability of Fluorometholone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluorometholone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluorometholone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluorometholone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluorometholone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluorometholone.Approved
MestranolThe serum concentration of Fluorometholone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluorometholone.Withdrawn
MethallenestrilThe serum concentration of Fluorometholone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFluorometholone may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneFluorometholone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneFluorometholone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Fluorometholone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Minaprine.Approved
MitotaneThe serum concentration of Fluorometholone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fluorometholone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluorometholone.Investigational
ModafinilThe serum concentration of Fluorometholone can be decreased when it is combined with Modafinil.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluorometholone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluorometholone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluorometholone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluorometholone.Investigational
NafcillinThe serum concentration of Fluorometholone can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluorometholone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluorometholone.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Fluorometholone.Investigational
NefazodoneThe metabolism of Fluorometholone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Fluorometholone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluorometholone.Approved
NetupitantThe serum concentration of Fluorometholone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fluorometholone can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluorometholone.Approved
NilotinibThe metabolism of Fluorometholone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluorometholone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluorometholone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Ofloxacin.Approved
OlaparibThe metabolism of Fluorometholone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluorometholone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluorometholone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fluorometholone.Vet Approved
OsimertinibThe serum concentration of Fluorometholone can be increased when it is combined with Osimertinib.Approved
OxandroloneFluorometholone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluorometholone.Approved
OxymetholoneFluorometholone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluorometholone.Withdrawn
PalbociclibThe serum concentration of Fluorometholone can be increased when it is combined with Palbociclib.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluorometholone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Fluorometholone can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Fluorometholone can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluorometholone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluorometholone.Approved, Vet Approved
PhenytoinThe metabolism of Fluorometholone can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorometholone.Approved, Investigational
PiretanideFluorometholone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluorometholone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluorometholone.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Fluorometholone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFluorometholone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Fluorometholone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Fluorometholone can be increased when combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Fluorometholone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluorometholone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fluorometholone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Fluorometholone can be increased when it is combined with Quinestrol.Approved
QuinethazoneFluorometholone may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rabies vaccine.Approved
RanolazineThe metabolism of Fluorometholone can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fluorometholone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluorometholone.Experimental, Investigational
RifabutinThe metabolism of Fluorometholone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fluorometholone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fluorometholone can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Fluorometholone can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fluorometholone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Fluorometholone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluorometholone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluorometholone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluorometholone.Approved
SaquinavirThe metabolism of Fluorometholone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Fluorometholone.Approved
SecoisolariciresinolThe serum concentration of Fluorometholone can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluorometholone.Approved, Investigational
SildenafilThe metabolism of Fluorometholone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fluorometholone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fluorometholone can be increased when it is combined with Simeprevir.Approved
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Fluorometholone.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Fluorometholone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fluorometholone.Investigational
St. John's WortThe serum concentration of Fluorometholone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololFluorometholone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Fluorometholone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluorometholone.Approved
SulfisoxazoleThe metabolism of Fluorometholone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluorometholone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluorometholone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Fluorometholone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Fluorometholone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fluorometholone.Approved
TelithromycinThe metabolism of Fluorometholone can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluorometholone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fluorometholone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluorometholone.Approved
TestosteroneFluorometholone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Fluorometholone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluorometholone.Approved
TiboloneThe serum concentration of Fluorometholone can be increased when it is combined with Tibolone.Approved
TiclopidineThe metabolism of Fluorometholone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluorometholone.Investigational
TocilizumabThe serum concentration of Fluorometholone can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluorometholone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluorometholone.Approved
TorasemideFluorometholone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluorometholone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Trichlorfon.Vet Approved
TrichlormethiazideFluorometholone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fluorometholone.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluorometholone.Investigational, Withdrawn
VenlafaxineThe metabolism of Fluorometholone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Fluorometholone can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Fluorometholone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinFluorometholone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluorometholone.Approved
ZeranolThe serum concentration of Fluorometholone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fluorometholone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Fluorometholone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluorometholone.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Fried, J.; U.S. Patent 2,852,51 September 16,1958; assigned to Olin Mathieson Chemical Corporation.

Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; US. Patent 2,867,637; January 6, 1959; assigned to The Upjohn Company
.
Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; U.S. Patent 2,867,638; January 6, 1959; assigned to The Upjohn Company.

Magerlein, B.J., Kagan, F. and Schlagel, C.A.; U.S. Patent 3,038,914; June 12, 1962; assigned to The Upjohn Company.

General ReferencesNot Available
External Links
ATC CodesD10AA01C05AA06D07XB04S01BA07D07AB06S01CB05S01BB03D07CB03S01CA07
AHFS Codes
  • 52:08.08
PDB EntriesNot Available
FDA labelDownload (64.7 KB)
MSDSDownload (72 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9956
Blood Brain Barrier+0.9716
Caco-2 permeable+0.8169
P-glycoprotein substrateSubstrate0.7834
P-glycoprotein inhibitor INon-inhibitor0.6791
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8397
CYP450 2C9 substrateNon-substrate0.8762
CYP450 2D6 substrateNon-substrate0.907
CYP450 3A4 substrateSubstrate0.7663
CYP450 1A2 substrateNon-inhibitor0.9149
CYP450 2C9 inhibitorNon-inhibitor0.8345
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9285
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9452
Ames testNon AMES toxic0.9025
CarcinogenicityNon-carcinogens0.9404
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3393 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9694
hERG inhibition (predictor II)Non-inhibitor0.5956
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Allergan pharmaceutical
  • Novartis pharmaceuticals corp
  • Alcon laboratories inc
Packagers
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic1 mg/mL
OintmentOphthalmic1 mg/g
Suspension / dropsOphthalmic1 mg/mL
Solution / dropsOphthalmic0.1 %
Suspension / dropsOphthalmic2.5 mg/mL
SuspensionOphthalmic0.25 %
SuspensionOphthalmic
SuspensionOphthalmic0.1 %
Prices
Unit descriptionCostUnit
FML Liquifilm 0.1% Suspension 15ml Bottle82.16USD bottle
FML Forte 0.25% Suspension 15ml Bottle60.98USD bottle
FML Liquifilm 0.1% Suspension 10ml Bottle60.17USD bottle
Flarex 0.1% Suspension 10ml Bottle50.7USD bottle
FML Forte 0.25% Suspension 10ml Bottle48.58USD bottle
Flarex 0.1% Suspension 5ml Bottle42.82USD bottle
FML Liquifilm 0.1% Suspension 5ml Bottle41.65USD bottle
FML-S Liquifilm 0.1-10% Suspension 10ml Bottle35.99USD bottle
Fluor-Op 0.1% Suspension 15ml Bottle30.99USD bottle
FML Forte 0.25% Suspension 5ml Bottle30.07USD bottle
Fluor-Op 0.1% Suspension 10ml Bottle25.99USD bottle
Fluor-Op 0.1% Suspension 5ml Bottle17.99USD bottle
Flarex 0.1% eye drops8.11USD ml
Fml liquifilm 0.1% eye drop6.27USD ml
Fml forte 0.25% eye drops5.09USD ml
Fluorometholone 0.1% drops3.25USD ml
Fml Forte 0.25 % Suspension2.96USD ml
Flarex 0.1 % Suspension1.96USD ml
Pms-Fluorometholone 0.1 % Suspension1.73USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point292-303Fried, J.; U.S. Patent 2,852,51 September 16,1958; assigned to Olin Mathieson Chemical Corporation. 
Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; US. Patent 2,867,637; January 6, 1959; assigned to The Upjohn Company
. Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; U.S. Patent 2,867,638; January 6, 1959; assigned to The Upjohn Company. 
Magerlein, B.J., Kagan, F. and Schlagel, C.A.; U.S. Patent 3,038,914; June 12, 1962; assigned to The Upjohn Company.
water solubility30 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.00HANSCH,C ET AL. (1995)
logS-4.1ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0166 mg/mLALOGPS
logP2.34ALOGPS
logP2.42ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)12.65ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity100.87 m3·mol-1ChemAxon
Polarizability40.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr: Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004 Dec;20(6):533-47. [PubMed:15684812 ]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  3. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953 ]
  4. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198 ]
  5. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445 ]
  6. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. El-Sankary W, Bombail V, Gibson GG, Plant N: Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos. 2002 Sep;30(9):1029-34. [PubMed:12167569 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23